Published • loading... • Updated
The First MIR 2026 of Endocrino, and for the 'Boom' Researcher in Obesity
Summary by redaccionmedica.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
The new era of drugs against obesity and diabetes is already felt in the MIR. And it is that Maite Losarcos has been the first aspirant of the whole process to choose Endocrinology this year, recognizing in Medical Writing that the scientific boom of GLP-1 agonist drugs present in drugs such as Wegovy, Mounjaro and Ozempic -based on active principles such as semaglutide or tirzepatide and authorized in our country for type 2 diabetes-, has contr…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
